Amarbir S Gill1, Jess C Mace2, Ryan Rimmer2, Vijay R Ramakrishnan3, Daniel M Beswick4, Zachary M Soler5, James Manor3, Richard R Orlandi1, Timothy L Smith2, Jeremiah A Alt1. 1. Department of Surgery, University of Utah, Salt Lake City, UT. 2. Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, OR. 3. Department of Otolaryngology, Head and Neck Surgery, University of Colorado-Anschutz Medical Campus, Aurora, CO. 4. Department of Otolaryngology-Head and Neck Surgery, University of California at Los Angeles, Los Angeles, CA. 5. Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, SC.
Abstract
BACKGROUND: The impact of multiple coexisting medical comorbidities on treatment outcomes in chronic rhinosinusitis (CRS) is unknown. In this study we sought to evaluate the effect of comorbidities on sinonasal quality of life (QOL) and general health utility values by utilizing the Functional Comorbidity Index (FCI) in CRS patients. METHODS: Patients with CRS were prospectively enrolled in a cross-sectional study of medical and surgical therapies. The 22-item Sino-Nasal Outcome Test (SNOT-22) and Medical Outcomes Study Short-Form 6D (SF-6D) scores were recorded at enrollment and 6-month follow-up; Lund-Kennedy endoscopy and Lund-Mackay computed tomography scores were recorded at enrollment. The FCI was calculated using the electronic medical record. The impact of cumulative comorbidity burden on baseline and posttreatment outcomes was assessed using univariate and bivariate correlations. RESULTS: A total of 428 participants with CRS were included. The average (mean standard ± deviation) FCI score was 3.03 ± 2.28 (range, 0-12). Significant linear correlations were identified between increasing FCI score and baseline SNOT-22 and SF-6D scores (R = 0.166, p = 0.001 and R = -0.245, p < 0.001, respectively). There was no correlation between FCI and change in SNOT-22 or SF-6D scores after CRS treatment (R = 0.066, p = 0.17 and R = -0.087, p = 0.074, respectively). Achievement of a minimally clinically important difference was also independent of FCI. CONCLUSION: Although cumulative comorbidity burden, as measured by FCI, is associated with worse baseline SNOT-22 and SF-6D scores, it does not appear to limit posttreatment improvement in either outcome measure. On average, patients with high comorbidity burden report substantial improvement in both QOL and health utility after CRS treatment, similar to those with fewer comorbidities.
BACKGROUND: The impact of multiple coexisting medical comorbidities on treatment outcomes in chronic rhinosinusitis (CRS) is unknown. In this study we sought to evaluate the effect of comorbidities on sinonasal quality of life (QOL) and general health utility values by utilizing the Functional Comorbidity Index (FCI) in CRS patients. METHODS: Patients with CRS were prospectively enrolled in a cross-sectional study of medical and surgical therapies. The 22-item Sino-Nasal Outcome Test (SNOT-22) and Medical Outcomes Study Short-Form 6D (SF-6D) scores were recorded at enrollment and 6-month follow-up; Lund-Kennedy endoscopy and Lund-Mackay computed tomography scores were recorded at enrollment. The FCI was calculated using the electronic medical record. The impact of cumulative comorbidity burden on baseline and posttreatment outcomes was assessed using univariate and bivariate correlations. RESULTS: A total of 428 participants with CRS were included. The average (mean standard ± deviation) FCI score was 3.03 ± 2.28 (range, 0-12). Significant linear correlations were identified between increasing FCI score and baseline SNOT-22 and SF-6D scores (R = 0.166, p = 0.001 and R = -0.245, p < 0.001, respectively). There was no correlation between FCI and change in SNOT-22 or SF-6D scores after CRS treatment (R = 0.066, p = 0.17 and R = -0.087, p = 0.074, respectively). Achievement of a minimally clinically important difference was also independent of FCI. CONCLUSION: Although cumulative comorbidity burden, as measured by FCI, is associated with worse baseline SNOT-22 and SF-6D scores, it does not appear to limit posttreatment improvement in either outcome measure. On average, patients with high comorbidity burden report substantial improvement in both QOL and health utility after CRS treatment, similar to those with fewer comorbidities.
Authors: Christopher John Staniorski; Caroline P E Price; Ava R Weibman; Kevin C Welch; David B Conley; Stephanie Shintani-Smith; Whitney W Stevens; Anju T Peters; Leslie Grammer; Alcina K Lidder; Robert P Schleimer; Robert C Kern; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2018-01-05 Impact factor: 3.858
Authors: Vijay R Ramakrishnan; Richard R Orlandi; Martin J Citardi; Timothy L Smith; Marvin P Fried; Todd T Kingdom Journal: Int Forum Allergy Rhinol Date: 2012-10-08 Impact factor: 3.858
Authors: Bryant R England; Harlan Sayles; Ted R Mikuls; Dannette S Johnson; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2015-05 Impact factor: 4.794
Authors: Lourdes Quintanilla-Dieck; Jamie R Litvack; Jess C Mace; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2012-06-13 Impact factor: 3.858
Authors: Quinn Orb; Jess C Mace; Adam S DeConde; Toby O Steele; Steve T Cox; Timothy L Smith; Jeremiah A Alt Journal: Int Forum Allergy Rhinol Date: 2015-11-04 Impact factor: 3.858
Authors: Carl M Philpott; Sally Erskine; Claire Hopkins; Nirmal Kumar; Shahram Anari; Naveed Kara; Sankalp Sunkaraneni; Jaydip Ray; Allan Clark; Andrew Wilson; Sally Erskine; Carl Philpott; Allan Clark; Claire Hopkins; Alasdair Robertson; Shahzada Ahmed; Naveed Kara; Sean Carrie; Vishnu Sunkaraneni; Jaydip Ray; Shahram Anari; Paul Jervis; Jaan Panesaar; Amir Farboud; Nirmal Kumar; Russell Cathcart; Robert Almeyda; Hisham Khalil; Peter Prinsley; Nicolas Mansell; Mahmoud Salam; Jonathan Hobson; Jane Woods; Emma Coombes Journal: Respir Res Date: 2018-06-27